Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹636 Cr
verified against source
Revenue YoY
65%
reported change
EBITDA
₹543 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Anupam Rasayan reported a strong FY26 with consolidated revenue of ₹2,384 crore (+65% YoY) and EBITDA of ₹543 crore (+32% YoY), driven by robust execution across agrochemicals, pharma, and performance materials. The company's diversification strategy reduced agro dependence from 76% in FY22 to 55% in FY26. Operating cash flow improved to ₹334 crore on better working capital management. Management guided for 20-30% standalone revenue growth over 3-5 years, supported by a ₹14,000 crore order book. Key strategic moves include the acquisition of JHawk Fine Chemicals (US) and a definitive agreement to acquire 43.3-48.5% of Bliss GVS Pharma, creating a full pharma platform. No major capex is planned beyond maintenance. Risk: Integration of multiple acquisitions may strain management bandwidth and execution.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects standalone business to grow at 20-30% annually, driven by order book conversion and new molecule commercialization.
- All plants are commercialized; current capacity sufficient for near-term growth. Only maintenance and efficiency capex planned.
- Management plans to increase Bliss's capacity utilization from 30% to 60-70%, leveraging Anupam's customer relationships and expertise.
- Management guided for a lower tax rate of around 25% on standalone operations.
Risks flagged
- Management is simultaneously integrating JHawk and Bliss, which could strain resources and execution if not managed carefully.
- An analyst raised concern that Anupam's move into finished dosage forms could conflict with existing CDMO customers. Management downplayed the risk, citing market size and selectivity.
- Bliss has low capacity utilization (30%) and has not engaged with investors recently. Turnaround may take longer than expected.
- The Bliss acquisition will add ~₹300 crore debt via NCDs, increasing consolidated gross debt to ~₹1,800 crore. While manageable, higher leverage could impact credit metrics.
Key quotes
- Our performance during the year was a result of strong execution across key business verticals, increasing contribution from high value chemistries and scale up of commercial molecules.
- If I look at the proforma basis business across the four companies, Anupam should be today around about ₹1,676 crores standalone, Tanfac ₹711, JHawk roughly ₹722, and Bliss ₹927, so total we should be looking at over ₹4,000 crores revenue and an EBITDA of around about ₹834 crores.
- We believe that the growth trajectory here in standalone business continues to grow across all the three verticals and then JHawk and then Bliss all three put together should be able to give a further fillip to the company's performance.
Research modules